EBITDA: Income before interest, taxes, depreciation and amortization.
Actinium Pharmaceuticals, Inc. (ATNM) had EBITDA of $-16.43M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-15.94M |
|
-- |
|
-- |
|
$16.64M |
|
$-16.64M |
|
$0.70M |
|
$-15.94M |
|
$-15.94M |
|
$-15.94M |
|
$-15.94M |
|
$-15.94M |
|
$-15.94M |
|
$-16.64M |
|
|
EBITDA |
$-16.43M |
31.20M |
|
31.20M |
|
$-0.51 |
|
$-0.51 |
|
| Balance Sheet Financials | |
$66.46M |
|
$0.32M |
|
$2.19M |
|
$68.65M |
|
$7.11M |
|
$0.01M |
|
$35.84M |
|
$42.95M |
|
$25.69M |
|
$25.69M |
|
$25.69M |
|
31.20M |
|
| Cash Flow Statement Financials | |
$-7.57M |
|
-- |
|
$-0.00M |
|
$73.23M |
|
$65.65M |
|
$-7.58M |
|
$8.87M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.35 |
|
-- |
|
-- |
|
0.00 |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.57M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-62.03% |
|
-62.03% |
|
-23.22% |
|
-62.01% |
|
$0.82 |
|
$-0.24 |
|
$-0.24 |
|